Does rosiglitazone increase myocardial infarction or cardiovascular-death risk in type 2 diabetes?

A 2007 meta-analysis found a higher risk of myocardial infarction than control, with a borderline increase in cardiovascular death.

Meta-analysis · New England Journal of Medicine 2007

Reference: Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en